[Antiemetic treatments associated with antineoplastic chemotherapy].
56 female patients with breast carcinoma and treated with polychemotherapy: adriamycin, vindesine, ciclophosphamide and 5-fluorouracil were studied, divided in three groups with different antiemetic schedule: group A 40 mg/iv of metoclopramide; group B 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone before beginning chemotherapy; and group C 2 mg/oral of lorazepam, 125 mg/iv methyl-prednisolone and 1 mg/kg/oral of metoclopramide previously to begin chemotherapy; at two and four hours of the first dose, metoclopramide was repeated the same doses (really) three doses each two hours. The combination of methylprednisolone-metoclopramide (B), decreases significantly the intensity, duration and frequency of nausea and vomiting, achieving total protection (no vomiting) in 4.34% of cycles of chemotherapy in group A, 32.2% in group B and 30.2% in group C (p less than 0.005 group A versus group B and A versus group C). Also we observed, without statistical analysis, better subjective tolerance to chemotherapy in patients receiving lorazepam associated to schedule B (schedule C). This makes it the recommended schedule.
Tres Sánchez
A
A
Servicio de Oncología Médica, Hospital Clínico Universitario, Zaragoza.
Sáez Martínez
M J
MJ
Mayordomo Cámara
J J
JJ
Guillén Lloveria
G
G
Sáenz Cusi
A
A
D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008787:Metoclopramide / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control
D000932:Antiemetics; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008787:Metoclopramide; D008140:Lorazepam; D005472:Fluorouracil; D008775:Methylprednisolone
Tratamientos antieméticos asociados a la quimioterapia antineoplástica.